A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma
Clinical trial NCT06656221 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06656221
- Sponsor
- Ruijin Hospital
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-01
- Primary completion
- 2026-12-01
- Enrollment
- 29
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.